Search Results
319 results found-
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season - Jul 17, 2023
https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season -
The results demonstrate that the A(H5N1) sa-mRNA influenza vaccine candidate induced an anti-HA and anti-NA neutralizing response raised by sa-mRNA influenza vaccines at a dose as low as 0.01 μg in mice and also induced HA-specific CD4+ T cells.
https://newsroom.csl.com/2022-10-05-CSL-Announces-Positive-Preclinical-Data-for-Self-Amplifying-Messenger-RNA-sa-mRNA-Influenza-Vaccine-Candidates -
In Belgium, where roughly 62% of older adults received a standard-dose egg-based influenza vaccine between 2015-2019, an analysis was conducted to investigate the potential cost effectiveness of using an adjuvanted quadrivalent influenza vaccine (aQIV).
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine vs High-Dose Influenza Vaccine in Older Adults with Influenza Risk Factors during the 2019-2020 U.S. Influenza Season.
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
CSL Seqirus has been an active and reliable partner to the UK across pandemic influenza vaccines for many years."
https://newsroom.csl.com/2023-09-26-CSL-Seqirus-secures-multi-year-pandemic-preparedness-agreement-as-part-of-its-continued-partnership-with-the-UK-government -
CSL Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing/csl-seqirus-manufacturing-technologies -
The researchers concluded that regardless of the severity of the flu season, preventing any saturation of acute hospital or ICU hospital beds would occur only if the vaccination rate for influenza vaccines was increased to 70 percent or higher.
https://newsroom.csl.com/2022-09-26-New-Data-at-OPTIONS-XI-Conference-Highlight-Burden-of-Seasonal-Influenza-on-Health-Systems-and-the-Need-for-Increased-Vaccination-Rates -
CSL Seqirus provides innovative solutions for pandemic preparedness and response.
https://www.csl.com/patients-public-health/vaccines/pandemic-response